Friday, 16 October 2026European Markets

TotalEnergiesGabon Stock Rises 9% So Far On Wednesday, Outperforms Market

Loading stream...

(vianews) - shares of totalenergiesgabon (cac 40: ec.pa) jumped 9.35% to €184.80 at 11:10 est on wednesday, following the last session's downward trend. cac 40 is falling 0.36% to €7,182.85, following the last session's upward trend. this seems, as yet, a somewhat bearish trend exchanging session today.

totalenergiesgabon's last close was €189.00, 5.5% under its 52-week high of €200.00.

about totalenergiesgabon

totalenergies ep gabon société engages in the mining, exploration, and production of crude oil in gabon. it also holds interests in operated and non-operated production fields. the company was formerly known as total gabon. the company was founded in 1949 and is headquartered in port-gentil, gabon. totalenergies ep gabon société is a subsidiary of totalenergies se.

earnings per share

as for profitability, totalenergiesgabon has a trailing twelve months eps of €72.11.

pe ratio

totalenergiesgabon has a trailing twelve months price to earnings ratio of 2.56. meaning, the purchaser of the share is investing €2.56 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.89%.

volatility

totalenergiesgabon's last week, last month's, and last quarter's current intraday variation average was 1.54%, 0.27%, and 0.88%.

totalenergiesgabon's highest amplitude of average volatility was 2.07% (last week), 0.59% (last month), and 0.88% (last quarter).

dividend yield

as stated by morningstar, inc., the next dividend payment is on sep 28, 2022, the estimated forward annual dividend rate is 72.09 and the estimated forward annual dividend yield is 39.52%.

moving average

totalenergiesgabon's worth is above its 50-day moving average of €177.25 and above its 200-day moving average of €168.84.

more news about totalenergiesgabon (ec.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com